01—Abstract
Summary
Summary of the 8-K filed December 11, 2025. Cited figures are marked; the original filing is the authoritative source.
Alnylam Pharmaceuticals (ALNY) disclosed in an 8-K filed December 11, 2025 that it entered into privately negotiated repurchase agreements on December 10, 2025 to buy back approximately $34.4 milliona in principal of its 1.00% convertible senior notes due 2027, for a total cash cost of about $51.9 million including accrued interest.
The implied price is roughly 151%b of par, a premium that reflects accrued interest and the conversion value of the notes, which means the company is paying above face value to retire this debt. The final cash price is not fixed. Part of the payment will be tied to the daily VWAP of Alnylam's common stock over a measurement period starting December 11, 2025, so the ultimate cost will move with the share price.
The repurchases are expected to close shortly after that period ends, subject to customary conditions. Once they close, about $362.8 millionc of the notes will remain outstanding. The capped call transactions tied to the original issuance are expected to stay in effect.
For investors, the transaction is a modest deleveraging step that reduces the convertible overhang and potential future dilution, consistent with the company's stated goal of building a self-sustainable financial profile under its "Alnylam P5x25" strategy. The filing does not disclose the funding source, the cash balance impact, or the accounting gain or loss, so those details should be checked in the next quarterly report.
02—Key points
Key Highlights
- Repurchase of about $34.4 million principal of 1.00% convertible senior notes due 2027 via privately negotiated agreements dated December 10, 2025
- Total cash cost of approximately $51.9 million including accrued and unpaid interest, implying a price above par
- Final price is subject to adjustment based on the daily VWAP of ALNY common stock over a measurement period beginning December 11, 2025
- Approximately $362.8 million aggregate principal of the notes will remain outstanding after the repurchases close
- Closing expected shortly after the measurement period, subject to customary conditions
- Capped call transactions linked to the original note issuance are expected to remain in effect
- Reduces convertible debt overhang and potential future dilution, supporting the Alnylam P5x25 strategy of self-sustainable financial performance
03—Questions
Frequently Asked Questions
Why is Alnylam paying more than the face value of the notes?
The $51.9 million total includes accrued and unpaid interest and a price component tied to the stock's trading value, so it is above the $34.4 million principal. Convertible notes often trade above par when the underlying share price is high, because their conversion value rises with the stock.
Will the final repurchase price change?
Yes. Part of the repurchase price depends on the daily volume-weighted average price of ALNY common stock over an agreed measurement period starting December 11, 2025, so the final cash amount may be higher or lower than the $51.9 million estimate.
How much convertible debt remains after the transaction?
About $362.8 million aggregate principal amount of the 1.00% convertible senior notes due 2027 is expected to remain outstanding once the repurchases close.
What happens to the capped call transactions?
The company says the capped call transactions it entered into with financial institutions when the notes were issued are expected to remain in effect despite the repurchases. These instruments can offset some dilution from conversion up to a specified cap.
How will Alnylam fund the repurchase and what is the accounting impact?
The filing does not disclose the funding source, the effect on cash and liquidity, or the gain or loss to be recognized. Investors should review the company's next Form 10-Q for these details.
04—Continue